Site Search
Professionals 411 results
Capabilities 79 results
Practice Area
Our nationally recognized Appellate & Critical Motions (ACM) Practice delivers sophisticated legal advocacy and analysis before trial, at trial, and on appeal. From state trial courts to the U.S. Supreme Court, our ACM attorneys identify, preserve, and present the critical legal issues that can make the difference between winning and losing.
Practice Area
Trial skills matter—even in a world where few disputes ever see the inside of a courtroom. Winston has built a reputation as a trial lawyers’ firm, featuring seasoned litigators who leverage extensive courtroom experience to meet our clients’ business and legal objectives. Our long history of taking cases to trial—and winning—provides our clients with tremendous settlement leverage with their adversaries, as well as a substantial likelihood of a favorable resolution if, and when, they go to trial.
Practice Area
Our attorneys have extensive experience counseling U.S. and multinational public companies across a range of industries in all aspects of corporate governance, securities, and compliance matters. We advise public companies, boards of directors and their committees, and senior executives on the corporate governance and compliance matters that public companies and their leadership confront—from board structuring and succession planning to shareholder activism and SEC regulation. Drawing on our experience as seasoned counselors, we keep clients abreast of evolving trends and best practices to proactively manage any governance or compliance issues. We have assembled one of the most experienced teams of any law firm in the country that’s counseling public companies.
Experience 104 results
Experience
|October 1, 2025
AA Mission Acquisition Corp. II - Initial Public Offering
Winston & Strawn LLP represented AA Mission Acquisition Corp. II, a blank check company, in the recent closing of its $100 million Initial Public Offering (IPO). The offering consisted of 10,000,000 units priced at $10.00 per unit, before deducting underwriting discounts and estimated offering expenses. The units began trading on the New York Stock Exchange (NYSE) under the ticker symbol “YCY.U” on October 1, 2025.
Experience
|September 9, 2025
Winston & Strawn LLP represented Greenland Exploration Limited in a landmark business combination with Pelican Acquisition Corporation (NASDAQ: PELI) and March GL Company. The transaction, structured as a merger agreement, will result in the formation of Greenland Energy Company, expected to be publicly listed on NASDAQ under the ticker symbol “GLND.” Winston advised Greenland Exploration on all aspects of the deal, including regulatory strategy, corporate structuring, and negotiation of the merger terms.
Experience
|June 25, 2025
Winston Secures Federal Circuit Affirmance of 101 Victory for Polycom
Winston secured an appellate victory for Polycom (now part of HP) when the Federal Circuit affirmed a judgment on the pleadings of patent-ineligibility in a lawsuit brought by directPacket Research, Inc. Working closely with HP, Winston argued that all claims of the asserted patent were directed to the abstract idea of translation via an intermediate protocol, with no inventive concept. The Northern District of California agreed, and the Federal Circuit unanimously affirmed, adopting Winston’s arguments. Eimeric Reig argued the appeal, working with HP and the Winston team, including Kathi Vidal, Kelly Hunsaker, Sam Lerner, Matt McCullough, and David Dalke.
Insights & News 2,062 results
Benefits Blast
|November 20, 2025
|10+ Min Read
2026 Proxy Season: A Look Ahead to Executive Compensation Issues and Considerations
As the 2026 proxy season approaches, companies should be mindful of developments in required executive compensation disclosures and related issues that may arise as they prepare proxy statements. This alert surveys key developments and provides specific action items for companies to consider.
Recognitions
|November 17, 2025
|Less Than 1 Min Read
Tom Melsheimer Named to D Magazine’s 2026 Dallas 500 List
Winston & Strawn Litigation Department Co-Chair Tom Melsheimer has been named to D Magazine’s 2026 Dallas 500 list. Dallas 500 is an annual publication from D CEO that profiles the most influential leaders in North Texas, across a wide spectrum of industries. The publication shares success strategies from the area’s top business, civic, and nonprofit leaders, their insights on industry trends, and their vision for Dallas’ future.
Recognitions
|November 12, 2025
|1 Min Read
Winston Partners Recognized in Lexology Index: Private Funds 2026
Winston & Strawn partners Basil Godellas and Scott Naidech have been recognized as leaders in the Lexology Index: Private Funds 2026 report. The report “identifies the foremost practitioners around the world including fund formation specialists and regulatory experts who advise and assist clients in relation to alternative asset classes such as private equity, venture capital, and hedge funds.”
Other Results 44 results
Law Glossary
Where Is a List of Biosimilar Drugs and Biologics That Have Been Approved in the U.S.?
The FDA maintains a list of biosimilar drugs that have been approved in the USA. This list can be found here.
Law Glossary
Maintained by the FDA, the Purple Book lists biologic products and biosimilar products that FDA has licensed under the Public Health Service Act. In addition, the Purple Book identifies the date each biologic obtained FDA licensure and indicates whether any biosimilar is interchangeable with its associated reference product.
Site Content
Blockchain is a technological system in which a digital list of records stored across a network. The network is a shared database comprised of a large number of computers. Blockchain is the primary technology for cryptocurrencies.